Tarsus Pharmaceuticals, Inc.TARSNASDAQ
Loading
EBITDA Over TimeContracting
Percentile Rank43
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Latest
$-55.88M
↓ 12% vs avg
Percentile
P43
Within normal range
Streak
2 yr
Consecutive growthContracting
Average
$-49.95M
Historical baseline
PeriodValueYoY Change
TTM$-55.88M+47.5%
2024$-106.48M+19.1%
2023$-131.67M-120.5%
2022$-59.70M-343.6%
2021$-13.46M+49.3%
2020$-26.56M-483.2%
2019$-4.55M-245.9%
2018$-1.32M-